New Study provides Vaginal Atrophy Global Pipeline Overview and Therapeutic Landscape, H2 2016

Vaginal atrophy disease is thinning drying and inflammation of the vaginal walls due to the body having less estrogen and also known as atrophic vaginitis. It afflicts nearly 90% of women after menopause. For many women, vaginal atrophy not only makes intercourse painful, but also leads to distressing urinary symptoms. Some of the symptoms include-

Vaginal Atrophy Disease

·         Vaginal dryness

·         Itching

·         Burning with urination

·         Urinary tract infections

·         Urinary incontinence

Risk factors includes smoking because it affects the blood circulation and also reduces the naturally occurring estrogens in body. The guide further provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Women's Health) industry with complete analysis by stage of development, monotherapy products, drug target, mechanism of action (MoA), route of administration and molecule type. Major treatment includes: topical (vaginal) estrogen and systemic estrogen therapy. Also, researchers are working to develop other treatments because of concerns about the long-term potential for even small doses of estrogen to increase the risk of endometrial and breast cancer. Women who cannot use estrogen may use a water-soluble vaginal lubricant as needed to relieve vaginal dryness and moisten tissue.

Some of the drug profiles mentioned in the report includes, Lasofoxifene tartrate, Oxycin, Prasterone, WC-3011 and others. These drug profiles undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with latest information. With many new drugs in the pipeline, the market is expected to grow smoothly in the coming years.

In the next section, guide also reviews key companies along with their major and minor projects. The list of companies involved in therapeutics development for Vaginal Atrophy Latest Report includes:

·         Ligand Pharmaceuticals, Inc.

·         Allergan Plc

·         EndoCeutics, Inc.

·         PEPTONIC medical AB

·         Foamix Pharmaceuticals Ltd.

·         Mithra Pharmaceuticals S.A.

The report enhances decision making capabilities of the reader and also help to create effective counter strategies for gaining competitive advantage. It also strengthens R&D pipelines by identifying new targets and MOA’s to produce best-in-class products.